Embecta Corp. (EMBC): M&A transaction — Embecta completes acquisition of Owen Mumford for £100M upfront plus up to £50M earnout

Embecta Corp.

Acquisition completed May 15, 2026; Owen Mumford is a UK-based medical device and drug-delivery technology manufacturer.
Upfront cash payment of £100M at closing; up to £50M additional based on Aidaptus auto-injector sales through June 2029.
Strategic move to transform embecta into a broad-based medical supplies company serving obesity, diabetes, autoimmune, and anaphylaxis markets.
Adds differentiated drug-delivery platform with Aidaptus next-generation auto-injector and strong IP portfolio.
Combines Owen Mumford's device design, molding, and assembly with embecta's global commercial infrastructure and manufacturing scale.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Embecta Corp. completed an acquisition involving Owen Mumford Holdings Limited for £100 million upfront cash plus up to £50 million milestone payments (closed 2026-05-15).

Action: acquisition
Counterparty: Owen Mumford Holdings Limited
Consideration: £100 million upfront cash plus up to £50 million milestone payments
Closing: 2026-05-15

Exact text from the filing

Ellen Owen, Kim Priddis and Nancy Millington. Pursuant to the terms and conditions of the Purchase Agreement, embecta acquired Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash) and will pay up to an additional £50 million upon the achievement of certain commercial milestones

View on SEC.gov

Browse all m&a transactions →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0000947871-26-000546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.